## Neil T Parkin

## List of Publications by Citations

Source: https://exaly.com/author-pdf/394548/neil-t-parkin-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11 375 9 13 g-index

13 539 8.3 3.01 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
11	HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. <i>Lancet Infectious Diseases, The</i> , <b>2018</b> , 18, 346-355	25.5	200
10	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. <i>Viruses</i> , <b>2020</b> , 12,	6.2	32
9	Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54 Suppl 4, S27	, <sub>3-9</sub> .6	24
8	Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21, e25193	5.4	24
7	Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. <i>Scientific Reports</i> , <b>2020</b> , 10, 1634	4.9	21
6	Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54 Suppl 4, S266-72	11.6	19
5	Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 1584-1597	7	19
4	Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations. <i>Viruses</i> , <b>2020</b> , 12,	6.2	14
3	Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. <i>Viruses</i> , <b>2020</b> , 12,	6.2	10
2	Are We Ready for NGS HIV Drug Resistance Testing? The Second "Winnipeg Consensus" Symposium. <i>Viruses</i> , <b>2020</b> , 12,	6.2	6
1	External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations. <i>Viruses</i> , <b>2020</b> , 12,	6.2	5